tiprankstipranks
Advertisement
Advertisement

IT:1BMRN Stock Latest News

Ascendis Pharma price target raised to $312 from $304 at Oppenheimer
The FlyAscendis Pharma price target raised to $312 from $304 at Oppenheimer
5d ago
ASND
BMRN
BioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics
PremiumCompany Announcements
BioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics
6d ago
8K
BMRN
BioMarin completes agreement to acquire Alesta Therapeutics
PremiumThe Fly
BioMarin completes agreement to acquire Alesta Therapeutics
6d ago
BMRN
Balanced Upside and Execution Risks Lead Richter to Maintain Hold on BioMarin After ASND Settlement and Voxzogo Expansion Plans
PremiumRatings
Balanced Upside and Execution Risks Lead Richter to Maintain Hold on BioMarin After ASND Settlement and Voxzogo Expansion Plans
6d ago
BMRN
BioMarin Settlement with Ascendis Clears Legal Overhang; Analyst Reaffirms Buy Rating and Maintains $114 Price Target
PremiumRatings
BioMarin Settlement with Ascendis Clears Legal Overhang; Analyst Reaffirms Buy Rating and Maintains $114 Price Target
6d ago
BMRN
BioMarin price target raised to $86 from $85 at Cantor Fitzgerald
PremiumThe FlyBioMarin price target raised to $86 from $85 at Cantor Fitzgerald
6d ago
ASND
BMRN
Ascendis Pharma price target lowered to $273 from $275 at Morgan Stanley
Premium
The Fly
Ascendis Pharma price target lowered to $273 from $275 at Morgan Stanley
6d ago
ASND
BMRN
BioMarin price target raised to $90 from $88 at Piper Sandler
Premium
The Fly
BioMarin price target raised to $90 from $88 at Piper Sandler
7d ago
ASND
BMRN
BioMarin Kept at Hold as YUVIWEL Royalties Lift DCF and Price Target Rises from $59 to $60 Amid VOXZOGO Headwinds
PremiumRatings
BioMarin Kept at Hold as YUVIWEL Royalties Lift DCF and Price Target Rises from $59 to $60 Amid VOXZOGO Headwinds
7d ago
BMRN
Analyst Sees BioMarin Undervalued After Ascendis Settlement, Modestly Raising Price Target to $105
PremiumRatings
Analyst Sees BioMarin Undervalued After Ascendis Settlement, Modestly Raising Price Target to $105
7d ago
BMRN
H.C. Wainwright trims Ascendis target, says litigation overhang removed
PremiumThe Fly
H.C. Wainwright trims Ascendis target, says litigation overhang removed
7d ago
ASND
BMRN
BioMarin price target raised to $105 from $104 at Jefferies
PremiumThe Fly
BioMarin price target raised to $105 from $104 at Jefferies
7d ago
ASND
BMRN
BioMarin price target raised to $60 from $59 at H.C. Wainwright
PremiumThe FlyBioMarin price target raised to $60 from $59 at H.C. Wainwright
7d ago
ASND
BMRN
BioMarin price target raised to $109 from $105 at Raymond James
Premium
The Fly
BioMarin price target raised to $109 from $105 at Raymond James
7d ago
ASND
BMRN
Ascendis Pharma price target lowered to $304 from $306 at BofA
Premium
The Fly
Ascendis Pharma price target lowered to $304 from $306 at BofA
7d ago
ASND
BMRN
Ascendis Pharma price target lowered to $330 from $333 at Jefferies
PremiumThe Fly
Ascendis Pharma price target lowered to $330 from $333 at Jefferies
7d ago
ASND
BMRN
Ascendis Pharma price target lowered to $326 from $328 at Stifel
PremiumThe Fly
Ascendis Pharma price target lowered to $326 from $328 at Stifel
7d ago
ASND
BMRN
BioMarin Pharmaceutical Secures Global CNP Licensing Settlement
PremiumCompany Announcements
BioMarin Pharmaceutical Secures Global CNP Licensing Settlement
7d ago
8K
BMRN
BioMarin to receive 20% royalty on net sales of Yuviwel from Ascendis Pharma
PremiumThe Fly
BioMarin to receive 20% royalty on net sales of Yuviwel from Ascendis Pharma
8d ago
ASND
BMRN
Trump Trade: U.S. considering new semiconductor tariffs
PremiumThe FlyTrump Trade: U.S. considering new semiconductor tariffs
11d ago
MU
AMD
White House to announce drug pricing deals with biotechs, Bloomberg reports
Premium
The Fly
White House to announce drug pricing deals with biotechs, Bloomberg reports
12d ago
ALKS
ALNY
BioMarin Acquisition of Alesta Therapeutics Reinforces Growth Strategy; Whitney Ijem Reiterates Buy Rating and Maintains $114 Price Target
Premium
Ratings
BioMarin Acquisition of Alesta Therapeutics Reinforces Growth Strategy; Whitney Ijem Reiterates Buy Rating and Maintains $114 Price Target
20d ago
BMRN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >